Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Fosun Pharma: FXS0683 tablets approved for clinical trials
Fosun Pharma announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., received approval from the National Medical Products Administration to conduct clinical trials of FXS0683 tablets for hematologic malignancies. FXS0683 is an orally administered small molecule innovative drug independently developed by the Group, representing a potent and highly selective next-generation Bcl-2 inhibitor, intended for the treatment of hematologic malignancies. As of February 2026, the Group’s total R&D investment in FXS0683 was approximately 27 million RMB. According to the latest data from IQVIA CHPA, in 2025, the sales of Bcl-2 inhibitors in China were approximately 338 million RMB.